FEMY - Femasys Continues to Run

2023-10-02 08:48:47 ET

(24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) continues to run, following two announcements last week, including 510(k) FDA Clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube.

We covered Femasys in June, when it was trading at $0.78 and again last week, at $0.93. Femasys is now trading at $3.47, up $0.49 (+16.44%), on 4.57M premarket shares traded.

Its 52-week range is $0.2479 to $3.62. It hit $4.30 in this morning’s premarket and we would like to see it consolidate to hold its gains.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is …

The post Femasys Continues to Run appeared first on 24/7 Market News .

For further details see: